Ychou, Marc http://orcid.org/0000-0001-7378-9469
Rivoire, Michel
Thezenas, Simon
Guimbaud, Rosine
Ghiringhelli, Francois http://orcid.org/0000-0002-5465-8305
Mercier-Blas, Anne
Mineur, Laurent
Francois, Eric
Khemissa, Faiza
Chauvenet, Marion
Kianmanesh, Reza
Fonck, Marianne
Houyau, Philippe
Aparicio, Thomas http://orcid.org/0000-0001-8834-6927
Galais, Marie-Pierre
Audemar, Franck
Assenat, Eric
Lopez-Crapez, Evelyne
Jouffroy, Claire
Adenis, Antoine http://orcid.org/0000-0003-3123-9746
Adam, René
Bouché, Olivier
Funding for this research was provided by:
Unrestricted grant from Merck Serono France
Article History
Received: 25 February 2021
Revised: 1 October 2021
Accepted: 17 November 2021
First Online: 6 January 2022
Ethics approval and consent to participate
: The study complied with the Declaration of Helsinki, good clinical practice guidelines, and other local laws. The study documents were approved by a French ethics committee, “Comité de Protection des Personnes Sud Méditerranée IV”. Patients provided written informed consent before enrolment.
: Not applicable.
: MY reported receiving honoraria from Amgen, Bayer, Merck, Roche, and Servier. MR has nothing to disclose. ST has nothing to disclose. RG reported personal fees from AAA, Amgen, Astra-Zeneca, BMS, P. Fabre, Novartis, Roche, Servier, outside the submitted work. FG served on external advisory boards for Roche; research funding from Roche, Genentech, Amgen, Enterome, Servier; received funding for a clinical trial from Astra-Zeneca, received fee for communication by Amgen, Astra-Zeneca, BMS, Sanofi, Merck-Serono, Servier and received fee for travel by Roche and Servier. AM-B has nothing to disclose. LM has nothing to disclose. EF reported personal fees from ROCHE, personal fees from SERVIER, personal fees from NOVARTIS, personal fees from MSD, outside the submitted work. FK reported personal feed from Sanofi, other fees from Roche (congress support), other fees from Ipsen (congress support), outside the submitted work. MC has nothing to disclose. RK has nothing to disclose. MF has nothing to disclose. PH has nothing to disclose. TA reported personal fees from Roche, personal fees from Servier, personal fees from Amgen, personal fees from Ipsen, personal fees from Sanofi, non-financial support from Bayer, outside the submitted work. M-PG reported other relevant financial interest from Roche (travel), other relevant financial interest from Amgen (travel, board), outside the submitted work. FA reported personal fees from Sanofi, personal fees from Merck, personal fees from Amgen, personal fees from Servier, personal fees from Roche, outside the submitted work. EA reported other fees (advisory board) from Roche, from Astrazeneca, from Ipsen, from Bayer, from Sanofi, from AMGEN, from AAA, outside the submitted work. EL-C has nothing to disclose, CJ has nothing to disclose. AA reported receiving honoraria from Bayer, Bristol-Myers Squibb, Merck-Sharp Dohme, Sanofi, and Servier. RA reported personal fees from Merck (congress presentation), personal fees from Sanofi (congress presentation), outside the submitted work. OB reported personal fees from ROCHE (self honoraria, advisory/consultancy), personal fees from AMGEN (self honoraria, speaker bureau/expert testimony), personal fees from MERCK KGaA (self honoraria, advisory/consultancy), personal fees from SERVIER (self honoraria, speaker bureau/expert testimony), personal fees from BAYER (self honoraria, advisory/consultancy), personal fees from PIERRE FABRE (self honoraria, speaker bureau/expert testimony), personal fees from Astra-Zeneca (self honoraria, advisory/consultancy), personal fees from Grunenthal (self honoraria, advisory/consultancy), personal fees from MSD (Self honoraria, advisory/consultancy), non-financial support from Roche (travel/accommodation/expenses) and non-financial support from Servier (travel/accommodation/expenses) outside the submitted work.